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Background:  Shigella  flexneri  2a lipopolysaccharide  50 is a nasally  delivered  subunit  vaccine  consisting  of
a  macromolecular  complex  composed  of  LPS,  IpaB,  IpaC  and  IpaD.  The  current  study  examined  vaccine
safety  and immunogenicity  across  a dose  range  and  the clinical  performance  of  a new  intranasal  delivery
device.
Methods:  Volunteers  (N =  36) were  randomized  to  receive  vaccine  via  the  DolphinTM (Valois  of  America,
Congers,  New  York)  intranasal  spray  device  at one  of three  doses  (240,  480,  and  690  g)  on  days  0,  14,
and  28.  Another  group  (N  =  8)  received  the  240  g dose  via  pipette.  Vaccine  safety  was  actively  monitored
and  antigen-specific  humoral  and mucosal  immune  responses  were  determined.
Results: There  were  no  serious  adverse  events  and  the  majority  of  adverse  events  (98%)  were  mild.  Anti-
body  secreting  cells  (ASC),  plasma,  and  mucosal  immune  responses  to  Shigella  antigens  were  detected  at
all  three  dose  levels  with  the  690 g dose  inducing  the highest  magnitude  and  frequency  of responses.
Vaccination  with  comparable  doses  of  Invaplex  50 via  the  DolphinTM resulted  in higher  plasma  and  ASC
immune  responses  as  compared  to  pipette  delivery.
Conclusion: In this  trial the  S.  flexneri  2a  Invaplex  50  vaccine  was  safe, well-tolerated  and  induced  robust
levels  of antigen-specific  intestinal  IgA  and  ASC  responses.  The  spray  device  performed  well  and  offered
an advantage  over  pipette  intranasal  delivery.
Published by Elsevier Ltd.
1. Background
Shigellosis is a leading cause of diarrheal disease worldwide
particularly in developing countries [1],  as well as a continu-
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ing problem for civilian travelers and military visiting endemic
regions [2–5]. Vaccine development remains a high priority given
the disease burden, increasing antibiotic resistance, and growing
appreciation of post-infectious sequelae associated with shigellosis
[6,7]. Shigella flexneri accounts for 30–60% of shigellosis cases in
developing regions necessitating coverage of prevalent S. flexneri
serotypes in a multivalent Shigella vaccine [1].
Several vaccine approaches to prevent shigellosis are under
active investigation including live-attenuated vaccines, inactivated
whole cell vaccines, subcellular vaccines and purified subunit vac-
cines such as O-specific polysaccharide conjugate vaccines [8,9].
The lack of a clear correlate of protection for Shigella vaccines
has hampered vaccine development over the past several decades
[8,10,11]. Even so, the importance of the serotype specific LPS anti-
gen is widely recognized and included as a component of all vaccine
approaches actively being pursued. Protein antigens, such as the Ipa
protein effectors of the type three-secretion system, remain attrac-
tive vaccine candidates due to their active role in pathogen-directed
0264-410X/$ – see front matter. Published by Elsevier Ltd.
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cellular invasion and the highly conserved sequences among these
essential virulence factors [12,13]. An effective Shigella vaccine
must deliver the appropriate immunogens and also stimulate the
proper immune response phenotype. For shigellosis, this likely
consists of local immunity within the intestinal tract. Oral immu-
nization may  achieve intestinal immunity but is often difficult to
consistently accomplish due to delivery restrictions, particularly
for inactivated or subunit vaccines. Mucosal immune responses
can also be achieved with intranasal immunization, although it
is not clear if this is an effective route for stimulating intestinal
immune responses in humans. The Shigella Invaplex 50 vaccine,
currently under clinical investigation, is a macromolecular complex
isolated from wild-type S. flexneri 2a that included both serotype
specific (LPS) and conserved antigens (IpaB, IpaC and IpaD) and
upon intranasal immunization stimulates robust intestinal and pul-
monary immune responses [14–16].
An initial phase 1 dose-escalation study evaluating the safety
and immunogenicity of the S. flexneri Invaplex 50 vaccine produced
under current Good Manufacturing Practices (cGMP) was recently
conducted using a pipette to deliver the vaccine intranasally
[16]. The Invaplex 50 vaccine was well tolerated and resulted
in antigen-specific humoral and mucosal immune responses at
doses ≥ 240 g. In the current study, the S. flexneri 2a Invaplex
50 vaccine was evaluated using a new lot of cGMP Invaplex 50
to expand the dose range and safety monitoring. Additionally, a
nasal delivery device was evaluated to facilitate vaccine delivery
and potentially induce a more robust mucosal immune response
due to distribution of the vaccine over a greater mucosal surface as
compared to pipette delivery.
2. Materials and methods
2.1. Manufacture of Invaplex 50 vaccine
The cGMP Invaplex 50 vaccine was prepared from virulent
S. flexneri 2a, strain 2457T as previously described [14,16] with
the following modifications. The 300 l culture was incubated
at 37 ◦C with an agitation speed of 200 rpm and air flow of
150 l/min, in animal product-free modified Antibiotic Medium 3
with 0.003% antifoam. The animal product-free modified Antibi-
otic Medium 3 contained the following components per liter:
Bacto yeast extract (Becton Dickinson, Sparks, MD), 1.5 g; Veg-
etable Peptone No. 1 (Oxoid/Remel, Lenexa, KS), 5 g; Bacto Dextrose
(Difco/BD, Sparks, MD)  1 g; sodium chloride (molecular-biology
tested, Sigma–Aldrich, St. Louis, MO), 3.5 g; potassium phos-
phate, dibasic (Sigma–Aldrich), 3.68 g; and, potassium phosphate,
monobasic (Sigma–Aldrich), 1.32 g. After 18 h of growth, the cul-
ture was harvested by centrifugation (Sharples AS-26 continuous
feed centrifuge) and an aliquot of the final culture was  used for
determination of bacterial colony forming units (cfu), gram stain,
purity, colony uniformity, percent Congo red positive colonies and
organism identity. The collected cells were extracted with water
and the resulting extract was applied to an anion-exchange col-
umn  (Q Sepharose High Performance, GE Healthcare) for isolation
of the Invaplex 50 product in an elution step consisting of 500 mM
NaCl in 20 mM  Tris, pH 9.0 as previously described [16]. The final
Invaplex 50 product was adjusted to 250 mM NaCl in 20 mM Tris, pH
8.8 and a final protein concentration of 3.46 mg  protein/ml, steril-
ized by filtration (0.22 m Millipak-20 filter unit) and dispensed in
1.0 ml  volumes into sterile, depyrogenated 2 ml  glass vials without
preservative. All vials were stored at −80 ◦C.
2.2. Analysis of cGMP S. flexneri 2a Invaplex 50 lot 1307
The total protein concentration was measured by the BCA (bicin-
choninic acid) assay (BioRad). SDS-PAGE Coomassie blue-stained
gels, silver-stained gels and western blots using anti-IpaB, IpaC and
S. flexneri 2a LPS mAbs [17,18] were used to assess the protein and
LPS composition in the Invaplex 50 product. The amount of IpaB and
IpaC in Invaplex 50 was determined using a modified ELISA pro-
cedure [19]. The LAL (Limulus amebocyte lysate) gel clot method
(Pryotell, Associates of Cape Cod, Inc.) was  used to measure the
quantity of lipopolysaccharide [16]. For the various analyses, the
animal product free-derived Invaplex 50 lot 1307 was compared
to previous cGMP lots 0994 and 0808 that were prepared from S.
flexneri 2a grown in Antibiotic Medium 3 containing animal derived
products [16].
2.3. Immunogenicity and efficacy in small animals
The immunogenicity and efficacy of the cGMP S. flexneri 2a
Invaplex 50 lot 1307 vaccine was  evaluated in mice and guinea
pigs. These procedures have been previously described for other
lots of cGMP Invaplex 50 [16].
2.4. Stability of Invaplex 50 vaccine
The Invaplex 50 product lot 1307, stored at −80 ◦C, was assessed
annually for antigen content by quantitative and qualitative assays
described above and immunogenicity in guinea pigs. At the time
of the study described in this report, lot 1307 had undergone three
immunogenicity evaluations at 4, 12 and 20 months and the serum
antibody response to S. flexneri 2a LPS and Invaplex 50 was evalu-
ated.
2.5. Stability of Invaplex 50 in the DolphinTM device
To improve the distribution of antigen on the nasal mucosa and
enhance antigen uptake, the DolphinTM system (Valois of Amer-
ica, Congers, NY), a single use prefillable, dispensing device was
used. The DolphinTM ensures reproducible droplet distribution on
the nasal mucosa with a consistent size of ∼100 m which is more
effective for antigen uptake by M cells, or antigen delivery to anti-
gen presenting cells (APCs) of the mucosal immune system [20]. The
DolphinTM intranasal spray device has not been used previously
to deliver vaccine products. A study was conducted to evaluate
the stability of the Invaplex 50 lot 1307 in the DolphinTM device
under conditions that simulated the product formulation and stor-
age in the device on the day of immunization. Multiple devices were
loaded with Invaplex 50 vaccine (230 l, 2.4 mg protein/ml) and
placed at 4 ◦C. At 0, 2, 4, 5 and 6 h a device was removed from the
refrigerator and discharged twice (100 l per spray) into a 50 ml
conical tube to collect the 200 l dose volume (spray). The dead vol-
ume  of the device is approximately 30 l. The sprayed vaccine was
centrifuged (2000 rpm, 5 min, 4 ◦C), collected and stored at −80 ◦C.
Prior to and following the discharge event the Dolphin device was
weighed to estimate the total volume discharged. Similar studies to
measure reproducibility of the spray volumes were also conducted
with saline. Collected samples were evaluated for total protein con-
centration by the BCA protein assay and the stability of IpaB, IpaC
and LPS by western blots (IpaB and IpaC) and silver-stained gels
(LPS). The relative content of LPS, IpaB and IpaC at each time point
(as compared to untreated sample) was  determined by densitom-
etry analysis of the bands in silver-stained gels or western blots.
2.6. Clinical trial design
The study was  conducted as an outpatient, single center, ran-
domized, double-blind study in 36 healthy adult volunteers to
assess vaccine safety and immunogenicity. Volunteers (12 per
group) received one of three intranasal dose amounts (240,
480 or 690 g) by the DolphinTM device. In addition, a fourth
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group of 8 volunteers received a 240 g intranasal dose deliv-
ered by pipette to serve as a bridging group to the preceding
trial [16].
2.7. Study population and enrollment criteria
Volunteers were healthy male and non-pregnant female adults
between 18 and 45 years of age recruited from the Balti-
more, MD–Washington, DC greater metropolitan area. They were
enrolled after an informed consent process consisting of a detailed
presentation of study material via a taped video, a comprehen-
sion test, and interview with an investigator. Volunteers were
excluded from enrollment if they had clinically significant acute
or chronic diseases, immunosuppressive disorders or medica-
tion, regularly used antidiarrheal, anti-constipation, or antacid
therapy, an abnormal stool pattern (<3 stools per week, or >3
stools per day), had participated in other investigational prod-
uct research, had a positive blood test for Hepatitis B surface
antigen, antibodies to Hepatitis C virus or Human Immunodefi-
ciency Virus-1, or had clinically significant abnormalities on basic
laboratory screening. Furthermore, given the intranasal route of
administration, volunteers were excluded if they had nasal polyps,
ulcers of the nasal mucosa, or clinically significant nasal septal
deviation, or a past/current medical history of chronic sinusitis
or chronic/seasonal rhinitis, rhinoplasty, reactive airway disease,
chronic obstructive pulmonary disease, chronic bronchitis, Bell’s
palsy, or were a current or recent (≤3 months) smoker. Based on
epidemiological data and the identification of Shigella LPS isolated
in the synovial fluid in reactive arthritis [21,22], volunteers with a
personal or family history of an inflammatory arthritis or positive
blood test for HLA-B27 were excluded. Lastly, volunteers with a his-
tory of microbiologically confirmed Shigella infection, prior receipt
of an experimental Shigella vaccine or live Shigella challenge, recent
travel (≤2 years) to a country where Shigella or other enteric infec-
tions are endemic, recent (≤3 years) occupation involving exposure
to Shigella species, or a plasma IgG titer ≥2500 to S. flexneri 2a LPS
were excluded.
2.8. Randomization, concealment and immunization procedures
Participants were randomized to one of three dose cohorts using
a ratio of 1:1:1 in block sizes of 3. The group receiving the Invaplex
50 vaccine via pipette was not randomized. A coding system was
used so that clinical investigators could not ascertain group assign-
ment. The vaccine was a clear liquid and did not differ visually
among the different dose levels. Depending on group assignment,
the volunteer received either 240, 480 or 690 g of vaccine in a
fixed volume of 200 l from two consecutive sprays (approximately
100 l/spray per nostril). To avoid anterior and posterior dripping
of the vaccine formulation out of the nose or into the digestive
tract, volunteers were vaccinated in a sitting position on an exam
table, with their head in a neutral or slightly tilted forward position.
The volunteer was instructed to breathe normally in through the
nose and out through the mouth, whereby a trained investigator
delivered the spray during inspiration. For delivery the device was
aimed at the medial angle of the eye (away from nasal septum) and
with the device kept at an angle less than 45◦ from vertical. After
each spray the subject was reclined (≤45◦) onto an exam table with
the head in neutral to slightly tilted back position, where the sub-
ject was instructed to continue breathing gently for 30–60 s. Nasal
sprays were given consecutively after an intervening delay. Vol-
unteers received 240 g of Invaplex 50 via nasal pipette in a total
volume of 200 l (100 l per nostril) as previously described [16].
Three doses of the vaccine were given at two-week intervals to all
subjects.
2.9. Safety monitoring
Adverse event monitoring was conducted using in-person
symptom surveillance, symptom diary log, and targeted physical
exams. Specifically, baseline clinical assessments including symp-
tom survey and local physical exam findings were conducted at
screening (up to 90 days prior to vaccination), 7 days prior to
immunization and on the day of immunization to record pre-
immunization findings. After each immunization, volunteers were
observed for 30 min  immediately followed by a symptom survey
and local physical exam. Adverse events were recorded prior to
and 30 min  after each immunization. Twice daily, for 7 days post-
vaccination, volunteers documented all adverse events in a diary.
Volunteers returned to the clinic 7 days after each immunization for
a focused exam and a diary review. The clinical observation period
concluded 28 days after the third vaccine dose. Solicited adverse
events included malaise, headache, rhinorrhea, nasal congestion,
nasal burning, nasal itching, sore throat, postnasal drip, cough,
sinus pain, sneezing, itching eyes, epistaxis and fever. Information
on any other symptoms, the use of any medications (prescrip-
tion and/or over-the-counter), non-planned medical consultations
or doctor’s visits, and hospitalizations were also collected. Sever-
ity of self-reported symptoms (adverse events) were recorded
according to the following grading scale: absent (Grade 0), mild
(Grade 1a = barely noticeable, Grade 1b = noticeable, but not inter-
fering with daily activities), moderate (Grade 2 = interfering with
daily activities), severe (Grade 3 = preventing daily activities), and
serious (Grade 4 = fatal or life-threatening, causing a prolonged
hospitalization, resulting in a significant, persistent, or permanent
disability, or requiring intervention to prevent permanent impair-
ment or damage). In addition to self-reporting of nasal adverse
reactions, standardized physical examinations with visualization
of the nasal mucosa, septum and mucosal blood vessel status after
the administration of each dose of the intranasal vaccine were
conducted by trained physicians (predominately by a single aller-
gist/immunologist). Examinations included an assessment for nasal
mucosa hyperemia, nasal discharge, nasal edema, pharyngeal ery-
thema, sinus tenderness, lymphadenopathy, conjunctival injection,
tearing, epistaxis, abnormal lung exam finding, abnormal cranial
nerve finding, and were similarly coded as mild, moderate, severe
and serious based on previously used grading criteria [16]. Blood
for clinical safety assessment was  drawn 7 days following the third
vaccine dose. In addition to grading severity of adverse events,
the degree of certainty (definite, probable, possible and unrelated)
with which an adverse event could be attributed to administra-
tion of the test article was determined by the principal investigator.
The recording of adverse events was solicited by a trained physi-
cian, with assignment of relationship made only by the principal
investigator. All aspects of the trial were closely assessed by an
independent medical monitor. Established criteria for discontinu-
ation of test article administration for all volunteers included any
individual experiencing any serious adverse events related to the
Invaplex 50 product and/or the occurrence of two unexpected,
severe adverse events related to the Invaplex 50 product.
2.10. Sample collections, schedules, and processing
The following samples were collected for immunological anal-
ysis: plasma for antigen-specific IgG and IgA (days 0, 14, 28, 35, 42,
and 56), peripheral blood mononuclear cells (PBMCs) for antigen-
specific antibody secreting cells (days 0, 21, and 35), stool (days
0, 21, 35, and 56), and nasal washes (day −7, 21, 35, and 56)
for secretory IgA. Blood samples were separated into plasma and
PBMC fractions as previously described [16]. Stool and nasal spec-
imens were frozen (−70 ◦C) immediately after collection and IgA
was extracted as described [16].
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2.11. Determination of antibody titers in plasma and mucosal
samples
The Shigella antigens, including S. flexneri 2a LPS and S. flexneri
2a Invaplex 50, used to measure the vaccine-specific immune
response have been previously described [16]. The S. flexneri 2a
Invaplex 50 was a research grade lot of Invaplex 50 that had similar
antigen content as the cGMP lot used for immunization of the vol-
unteers. For immunoassays, antigen plates were coated overnight
at 4 ◦C with 100 l of LPS or Invaplex 50 diluted to 10 or 0.5 g/ml,
respectively, in carbonate coating buffer (pH 9.8). IgG and IgA end-
point titers specific for Shigella antigens were determined by ELISA
from plasma samples as previously described [16]. The endpoint
titer was defined as the reciprocal of the last dilution of a given
sample that produced an OD405 value of ≥0.2.
Nasal and fecal samples were assessed by ELISA for anti-S.
flexneri 2a LPS and anti-S. flexneri 2a Invaplex 50 IgA titers as pre-
viously described [16,23] with minor modifications. First, total IgA
in stool extracts and nasal extracts was determined by a capture
ELISA [24] using goat anti-human F(ab′)2 (Jackson Laboratories) as
capture antibody and HRP conjugated goat anti-human IgA (KPL,
Rockville, MD)  as the detecting antibody. Total IgA concentrations
were then adjusted to 1 mg/ml  by either concentration with Ami-
con Ultra 30,000 MWCO  filters (Millipore, Billerica, MA)  or dilution
and antigen-specific endpoint titers were determined as outlined
above. Endpoint titers of mucosal specimens were calculated as the
reciprocal of the highest dilution giving a net (antigen wells−BSA
coated control wells) absorbance value of ≥0.15.
2.12. Antibody secreting cell (ASC) assay
IgA and IgG ASCs specific for S. flexneri 2a LPS and S. flexneri
2a Invaplex 50 were enumerated by an ASC assay using samples
collected on days 0, 21, and 35 as previously described [16] using
S. flexneri 2a LPS, Invaplex 50, and BSA diluted to 10, 0.5, or 1 g/ml
(100 l/well), respectively, in carbonate coating buffer (pH 9.8).
2.13. Study endpoints and definitions
The primary safety outcome was local or systemic reactions
occurring in the 7-day post-vaccination period. A priori immuno-
logical outcomes for responders were established as follows: (1)
ASC positive response: ≥10 antigen-specific ASC per 106 PBMCs;
(2) seroconversion: ≥4-fold increase over the baseline titer; and (3)
fecal and nasal IgA responders: ≥4-fold increase over the baseline
titer after normalizing for total IgA. Only volunteers that received
at least two doses of vaccine were included in the immunological
analysis.
2.14. Data analysis and statistical considerations
Rates of all adverse events (related and unrelated) observed
during the follow-up period after vaccinations were analyzed to
compare within and across dose levels. For immunological analy-
sis, qualitative (responder rates) and quantitative assessments (log
transformed values) were made in addition to evaluation of the
kinetics of the immune response. Nonparametric tests were used
for comparison between groups (Kruskal–Wallis for continuous
data and Fisher’s exact test for categorical data). Paired t-tests were
used to compare individual post-vaccination to baseline response
within each treatment group. All statistical tests were interpreted
in a two-tailed fashion using alpha ≤ 0.05; no adjustments were
made for multiple comparisons.
As this was a phase 1 dose-finding clinical trial, no formal
sample size calculation was performed; however, each treatment
group sample size (minimum n = 10, with exception of bridging
pipette group) ensured that the probability of detecting at least
one adverse event in the group was 80%, provided that the true
adverse event rate exceeded 15%. Furthermore, using a binomial
probability formula for no observed severe adverse events within
the 36 volunteers receiving at least one dose of test article via the
DolphinTM device yielded a 95% confidence interval of 0–11%.
3. Results
3.1. Characteristics of the Invaplex 50 vaccine lot 1307
The composition of S. flexneri 2a Invaplex 50 lot 1307 was
comparable to Invaplex 50 lot 0994 that was  used in the initial
phase 1 study [16]. Invaplex 50 lot 1307 contained 12.4 g IpaB/mg
total protein, 18.8 g IpaC/mg total protein and 6 × 106 EU/ml
(567 g LPS/ml) or 1.7 × 106 EU/mg total protein (164 g LPS/mg
total protein). For comparison, lot 0994 contained 8.4 g IpaB/mg
total protein, 18.1 g IpaC/mg total protein and 1.0 × 106 EU/mg
total protein [16]. At the time of manufacture, the immunogenic-
ity and efficacy of lot 1307 was  assessed in mice and guinea pigs
(Table 1). Using S. flexneri 2a LPS and research grade Invaplex 50
as ELISA antigens, S. flexneri 2a Invaplex 50 lot 1307 stimulated a
greater than 16-fold increase (p < 0.001) in titer in all immunized
mice and a greater than 8-fold increase (p < 0.001) in all immu-
nized guinea pigs as compared to the saline control group. At the
time of manufacture lot 1307 provided protective immunity in both
mice and guinea pigs. In mice, using the lethal lung model, 15 of 15
challenged mice were protected (p < 0.0001; control mice 11 of 13
mice died). In guinea pigs, using the keratoconjunctivitis model,
83% (n = 12) of the animals were protected (p < 0.001; 100% saline
controls (n = 10) were infected with scores of 3). The level of protec-
tion achieved with lot 1307 (made from cultures grown in animal
product-free media) was comparable to previously described cGMP
Invaplex 50 lots 0994 and 0808 made from S. flexneri 2a grown
in animal product-containing media. Immunogenicity assessments
were also conducted periodically on the product as part of the sta-
bility program and showed comparable titers at 12 months and 20
months post-manufacture (data not shown).
3.2. Stability of S. flexneri 2a Invaplex 50 lot 1307 vaccine
At the time of the clinical trial described in this manuscript
the IpaB, IpaC and LPS antigens in lot 1307 showed no evidence
of degradation or decreased quantities as determined by west-
ern blots and SDS-PAGE. Similarly the immunogenicity in guinea
pigs at the time of the trial was comparable to that determined
at the time of manufacture. Serum IgG titers specific for LPS and
Invaplex 20 months post-manufacture were comparable in mag-
nitude (GMT 1091 and 3800, respectively) to those induced after
vaccination 4 months post-manufacture (GMT 1440 and 2036,
respectively) with all animals responding to vaccination with a
greater than or equal to 4-fold increase in antibody titers over base-
line (day 0). Similar trends were evident in the serum IgA titers,
with comparable levels of anti-Invaplex 50 and anti-LPS antibodies
induced after vaccination with product stored at −80 ◦C for up to
20 months.
The stability of the Invaplex 50 vaccine in the DolphinTM device
was determined under conditions comparable to those used for
immunizations in the clinic. The quantity of each antigen was con-
sistent over the 6 h time course and increased degradation of IpaB
and IpaC was  not detected by densitometry western blot analysis
using untreated vaccine as the baseline. The LPS content ranged
from 86 to 130% of the untreated value, IpaB content ranged from
85 to 135%, and IpaC content ranged from 88 to 111%. This suggests
that the Invaplex 50 product was stable when stored in a Dolphin
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Table  1
Results of efficacy experiments in micea and guinea pigsb with after intranasal immunization with S. flexneri 2a Invaplex 50 lots 1307, 0994 and 0808.
Animal model Vaccinec (dose) Anti-S. flexneri 2a
LPS serum IgG
Anti-S. flexneri 2a
Invaplex serum IgG
Number deaths/
total
% death Efficacye p-Valuef
Mouse lung Invaplex 50 lot 1307 (5 g) 360 ± 531d 6617 ± 3864 0/15 0 100% <0.001
Invaplex 50 lot 0994 (5 g) 360 ± 531 3800 ± 2036 0/15 0 100% <0.001
Invaplex 50 lot 0808 (5 g) 207 ± 121 5014 ± 3527 1/15 7 92% <0.001
Saline 90 ± 0 90 ± 0 11/13 85 – –
Animal  model Vaccinec (dose) Anti-S. flexneri 2a
LPS serum IgG
Anti-S. flexneri 2a
Invaplex serum IgG
Number with
disease/total
% disease Efficacye p-Valuef
Guinea pig
keratoconjunctivitis
Invaplex 50 lot 1307 (25 g) 1440 ± 2556 2036 ± 789 2/12 17 83% <0.001
Invaplex 50 lot 0994 (25 g) 1440 ± 984 2286 ± 1683 4/12 33 67% 0.002
Invaplex 50 lot 0808 (25 g) 360 ± 511 2286 ± 2485 4/12 33 67% 0.002
Saline 90 ± 0 90 ± 0 10/10 100 – –
a Mice (15 per group) were immunized intranasally three times at two  week intervals followed by an intranasal challenge with 1.5 × 107 cfu S. flexneri 2a (2457T) three
weeks after the final immunization. Deaths (endpoint) were recorded daily for two weeks after challenge.
b Guinea pigs were immunized intranasally, three times at two-week intervals. Guinea pigs were challenged 3 weeks after the final immunization with S. flexneri 2a strain
2457T,  2.9 × 108 cfu/eye. Eyes of each animal were monitored daily for inflammation and keratoconjunctivitis. Disease was graded according to Hartman et al. [35]. Results
on  day 5 were used to determine protection. Scores of 2 and 3 were considered positive for disease.
c Invaplex 50 lots 0994 and 0808 are described in Tribble et al. [16].
d Geometric mean titer (GMT) ± standard deviation.
e Efficacy was calculated by the formula: [{% disease or death (controls) − % disease or death (vaccines)}/% disease or death (controls)] × 100.
f p-Value was  determined by the Fisher’s exact test.
nasal spray device at 4 ◦C for up to 6 h. For clinical use, a 5-h limi-
tation was applied for the Invaplex 50 product stored in the device
at 4 ◦C.
3.3. DolphinTM device spray reproducibility
The DolphinTM is a unit-spray device (Fig. 1) designed to deliver
200 l of product in two, 100 l sprays. The manufacturer (Valois
of America, Inc.) has determined that the mean delivery volume
is 200.1 l with a range of 193.9–207.5 l. Less than 1% of the
spray droplets from each spray are smaller than 10 m in diam-
eter which reduces the probability of the sprayed product entering
the lungs. The average diameter of the droplets is 100.9 ± 11.5 m
for the first spray and 81.7 ± 10.4 m for the second spray. In the
Walter Reed Army Institute of Research (WRAIR) laboratory the
mean spray volume for saline was 196.9 ± 4.3 l and for Invaplex
50 it was 194.9 ± 10.1 l. During clinical trials it was not possible
to determine the actual volume sprayed but the amount retained
in the device was determined for each of the three dose amounts of
Invaplex 50 given during the trial (Table 2). Although the retained
volume ranged from 19.7 l to a maximum of 77.1 l there was  no
Fig. 1. The DolphinTM unit-spray device. (Valois of America, Inc.)
significant difference in the retained volumes between the three
dose groups.
3.4. Clinical trial results
3.4.1. Demographics
A total of 120 volunteers initiated the informed consent pro-
cess and 112 signed a written informed consent and underwent
pre-study screening (Fig. 2). Reasons for individuals (44 subjects)
not meeting eligibility criteria included disqualifying medical his-
tory or physical exam (n = 6, 14%), clinically significant, persistent
abnormal baseline biochemistry or hematology tests (n = 15, 34%),
positive blood test for HBsAG or antibodies to HCV or HIV-1 (n = 4,
9%), history of reactive arthritis (n = 1, 2%), and positive blood test
for HLA-B27 (n = 5, 11%), current smoker (n = 1, 2%), serum IgG
titer to Shigella LPS ≥ 2500 (n = 4, 9%), and recent travel to Shigella
endemic region (n = 8, 18%). Among the remaining 44 enrolled par-
ticipants, 36 were randomized to the three cohorts immunized with
the Dolphin device and received at least one dose of study vaccine.
Eight other enrolled participants were administered 240 g vac-
cine with a pipette. The mean age of participants was 36.1 years
(range 19–45 years). While there were no significant differences in
the gender (52.8% male) or race (66.7% African-American) between
vaccine groups, the 690 g dose group was younger (p = 0.002) than
the 240 or 480 g dose groups (Table 3).
3.4.2. Safety and clinical adverse events
There were no serious adverse events or adverse events
that met  stopping criteria. Additionally, there were no vaccine-
associated, clinically significant abnormalities in hematology or
Table 2
Retained S. flexneri 2a Invaplex 50 volume in DolphinTM device after vaccine
administration.
Dose amount (g)
240 g 480 g 690 g
N 36 34 30
Retained volume (l) 35.1 ± 8.9a 34.5 ± 10.8 39.5 ± 10.9
Minimum (l) 21.4 22.1 19.7
Maximum (l) 58.9 77.1 66.1
Target retained volume = 30 l.
a Mean ± std deviation.
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Fig. 2. Study participant flow diagram. The flow diagram outlines the status (screened, excluded, enrolled) of all study participants. Of the 44 enrolled subjects, 36 were
randomly assigned to groups (240 g, 480 g and 690 g) immunized with the Dolphin device. The remaining 8 enrolled subjects were administered 240 g Invaplex 50 with
a  pipette. The final assessment column indicates the number of volunteers that underwent safety evaluation and immunological lab evaluations after the final immunization.
clinical chemistry values. Table 4 details the surveyed signs and
symptoms of volunteers receiving at least one vaccine dose.
The majority (98%) of the vaccine-attributable adverse events
(AE) were mild, self-limiting, and resolved within 72 h after
immunization. No volunteers reported any vaccine-attributable
severe or serious adverse events. The most commonly reported
vaccine-associated symptoms were rhinorrhea (31%) and nasal
congestion (33%) with no significant differences in frequencies
between groups. Sneezing and nasal itching were also observed
relatively frequently (both in 28% of the volunteers). The Cochran-
Armitage Chi-square tests for trend of increasing AE frequency
with increasing Invaplex 50 dose approached statistical signifi-
cance for transient nasal itching (p = 0.07), coughing (p = 0.08) and
sneezing (p = 0.07). The frequency of headaches, nasal congestion,
nasal itching, sore throat and sneezing decreased upon repeated
vaccination (Cochran-Armitage Chi-square p-value < 0.05) with
the most evident decreases occurring between dose 1 and
dose 2.
Adverse events within the first 30 min  after vaccine administra-
tion were reported and most frequently included sneezing (18.6%),
post-nasal drip (18.6%), nasal itching (16.3%) and nasal congestion
(16.3%). Adverse events were also reported between 24 h and 72 h
following vaccination and included nasal congestion (32.6%) and
post-nasal drip (16.3%). Lymphadenopathy (cervical) and pharyn-
geal erythema were observed on clinical exam and coded as at least
possibly related to the investigational product in 14% and 6% of vol-
unteers, respectively. The development of mucosal alterations did
not occurr during the study. Two  cases of subjective fever were
reported in the 240 g dose groups delivered with the DolphinTM
and two  cases with the pipette. There were no significant differ-
ences in the frequency of any physical exam findings between the
vaccine groups. Two  possibly related vaccine-attributable moder-
ate adverse events (cough and sore throat) were reported by a single
subject in the 690 g dose group just over 1 week after receipt of
the initial vaccine dose.
3.5. Immunological responses
Of the 33 volunteers that received the minimum number
(two) of vaccinations required for immunologic evaluation via the
intranasal spray device, 11 were in the 240 g dose group, 10 in
the 480 g dose group and 12 in the 690 g dose group. A total
Table 3
Baseline characteristics of study participants.
Invaplex 50 dosea 240 g (Pipette) 240 g (DolphinTM) 480 g (DolphinTM) 690 g (DolphinTM)
N 8 12 12 12
Median  (IQR) age 28.0 (24.0, 32.0) 41.0 (32.5, 43.5) 41.5 (36.0, 42.5) 30.5 (24.0, 38.0)
Gender
n  (%) male 5 (62.5) 7 (58.3) 7 (58.3) 5 (41.7)
n  (%) female 3 (37.5) 5 (41.7) 5 (41.7) 7 (58.3)
Race/ethnicity
n  (%) African-American 2 (25.0) 7 (58.3) 8 (66.7) 9 (75.0)
n  (%) Caucasian 3 (37.5) 5 (41.7) 3 (25.0) 1 (8.3)
n  (%) other 3 (37.5) 0 (0.0) 1 (8.3) 2 (16.7)
N = number receiving at least one immunization; IQR = interquartile range.
a Dose amount represents total protein.
M.S. Riddle et al. / Vaccine 29 (2011) 7009– 7019 7015
Table  4
Number (percent) of volunteers experiencing surveyed signs and symptoms post-vaccination with S. flexneri 2a Invaplex 50.
Adverse event 240 g (Pipette) 240 g (DolphinTM) 480 g (DolphinTM) 690 g (DolphinTM)
Related Unrelated Related Unrelated Related Unrelated Related Unrelated
Solicited symptoms
Malaise 1 (12.5) 3 (37.5) 1 (8.3) 3 (25.0) 0 (0.0) 2 (16.7) 1 (8.3) 2 (16.7)
Headache 1 (12.5) 1 (12.5) 1 (8.3) 4 (33.3) 1 (8.3) 1 (8.3) 2 (16.7) 6 (50.0)
Rhinorrhea 1 (12.5) 2 (25.0) 4 (33.3) 4 (33.3) 3 (25.0) 1 (8.3) 4 (33.3) 4 (33.3)
Nasal  congestion 2 (25.0) 4 (50.0) 7 (58.3) 5 (41.7) 2 (16.7) 4 (33.3) 3 (25.0) 7 (58.3)
Nasal  burning 1 (12.5) 0 (0.0) 1 (8.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (8.3)
Nasal  itching 1 (12.5) 0 (0.0) 1 (8.3) 1 (8.3) 4 (33.3) 1 (8.3) 5 (41.7) 3 (25.0)
Sore  throat 1 (12.5) 1 (12.5) 2 (16.7) 2 (16.7) 0 (0.0) 1 (8.3) 4 (33.3) 3 (25.0)
Postnasal drip 2 (25.0) 1 (12.5) 2 (16.7) 2 (16.7) 2 (16.7) 1 (8.3) 5 (41.7) 2 (16.7)
Cough 0 (0.0) 3 (37.5) 1 (8.3) 3 (25.0) 0 (0.0) 2 (16.7) 4 (33.3) 5 (41.7)
Sinus  pain 0 (0.0) 1 (12.5) 0 (0.0) 0 (0.0) 0 (0.0) 1 (8.3) 1 (8.3) 2 (16.7)
Sneezing 0 (0.0) 3 (37.5) 1 (8.3) 2 (16.7) 4 (33.3) 1 (8.3) 5 (41.7) 6 (50.0)
Itching eyes 0 (0.0) 0 (0.0) 1 (8.3) 0 (0.0) 1 (8.3) 0 (0.0) 2 (16.7) 1 (8.3)
Nose  bleed 0 (0.0) 0 (0.0) 0 (0.0) 2 (16.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Fever  0 (0.0) 2 (25.0) 1 (8.3) 2 (16.7) 0 (0.0) 1 (8.3) 1 (8.3) 2 (16.7)
Physical exam findings
Nasal mucosa hyperemia 1 (12.5) 4 (50.0) 1 (8.3) 8 (66.7) 0 (0.0) 7 (58.3) 0 (0.0) 8 (66.7)
Nasal  discharge 1 (12.5) 5 (62.5) 1 (8.3) 9 (75.0) 0 (0.0) 10 (83.3) 0 (0.0) 9 (75.0)
Nasal  edema 0 (0.0) 4 (50.0) 1 (8.3) 8 (66.7) 0 (0.0) 11 (91.7) 0 (0.0) 12 (100)
Pharyngeal erythema 0 (0.0) 1 (12.5) 0 (0.0) 2 (16.7) 0 (0.0) 3 (25.0) 2 (16.7) 3 (25.0)
Sinus  tenderness 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (8.3)
Lymphadenopathy 0 (0.0) 2 (25.0) 2 (16.7) 0 (0.0) 2 (16.7) 2 (16.7) 1 (8.3) 0 (0.0)
Conjunctival injection 0 (0.0) 5 (62.5) 0 (0.0) 2 (16.7) 0 (0.0) 1 (8.3) 0 (0.0) 2 (16.7)
Tearing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Epistaxis 0 (0.0) 0 (0.0) 0 (0.0) 1 (8.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Abnormal lung exam finding 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (8.3)
Abnormal cranial nerve finding 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
of 7 volunteers received at least two doses of vaccine via pipette
(Table 5).
3.5.1. Antigen-specific ASCs
LPS and Invaplex 50-specific IgG and IgA ASCs were determined
for individual volunteers from PBMCs collected before vaccination
and 7 days following each dose. Baseline (day 0) antigen-specific
ASCs were at undetectable levels in all but two  volunteers with
≤3 per 106 PBMCs. Positive antigen-specific ASC responses were
detected in volunteers from all study groups. In general, antigen-
specific IgA and IgG ASCs peaked following the second vaccination
in the majority (75–77%) of volunteers regardless of vaccine dose
used for immunization or the antigen specificity of the assay (data
not shown).
The 690 g dose elicited the highest frequency of responders
with 75% and 58% of volunteers having Shigella-specific IgA and IgG
ASC responses to S. flexneri 2a Invaplex 50, respectively (Table 5;
Fig. 3A). The majority (58%) of volunteers immunized with the
690 g dose also had positive IgG and IgA ASC responses to LPS and
Invaplex 50. Among volunteers receiving the highest dose (690 g),
75% had either IgA ASCs or IgG ASCs directed to one of the anti-
gens, although the magnitude of the responses varied (IgA range
10–227; IgG range 11–373). Antigen-specific immune responses
elicited after immunization with 690 g dose of Invaplex 50 in each
volunteer is summarized in Table 6. In terms of the magnitude of
the antigen-specific ASC responses, peak Invaplex 50-specific IgA
and IgG ASCs were significantly higher in volunteers immunized
with 690 g as compared to 240 or 480 g of the vaccine. Further-
more, several volunteers in the 480 and 690 g dose groups had IgG
and IgA-secreting ASCs that exceeded 100 (Fig. 3A). In general, the
lower quantity of Invaplex 50 used for immunization resulted in a
lower frequency of ASC responders (Table 5) and generally lower
magnitude of ASCs in those volunteers that did respond (Fig. 3A) in
a dose dependent manner. The responder rate in the 240 g dose
Table 5
Frequency of volunteersa exhibiting an immune response to each of evaluated parameters.
Antigen Assayb Study groups
240 g (Pipette) (n = 7) 240 g (DolphinTM) (n = 11) 480 g (DolphinTM) (n = 10) 690 g (DolphinTM) (n = 12)
Invaplex 50 IgA (ASCs) 1 (14) 2 (18)c 2 (20) 9 (75)
IgG (ASCs) 1 (14) 3 (27) 2 (20) 7 (58)
IgA  (fecal) 2 (29) 7 (64) 6 (60) 7 (58)
IgA  (nasal) 0 1 (9) 1 (10) 4 (33)
IgA  (plasma) 0 0 1 (10) 6 (50)
IgG (plasma) 0 3 (27) 3 (30) 2 (17)
LPS IgA  (ASCs) 1 (14) 3 (27) 2 (20) 7 (58)
IgG (ASCs) 1 (14) 4 (36) 2 (20) 7 (58)
IgA  (fecal) 1 (14) 7 (64) 7 (70) 6 (50)
IgA  (nasal) 1 (14) 1 (9) 2 (20) 6 (50)
IgA  (plasma) 0 1 (9) 1 (10) 3 (25)
IgG (plasma) 0 5 (46) 4 (40) 5 (42)
a Limited to volunteers providing specimens after receipt of at least 2 vaccine doses.
b Immune response definitions: serologic/fecal/nasal (≥4-fold rise from baseline) and ASC (≥10 antigen-specific cells per 106 PBMC).
c Data expressed as the number of volunteers with an immune response (%).
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Fig. 3. Peak immune responses after intranasal immunization with S. flexneri 2a
Invaplex 50. Panel A: antibody secreting cell responses to Invaplex 50 (IgA (©); IgG
())  and LPS (IgA (); IgG ()). Panel B: mucosal IgA responses to Invaplex 50 (fecal
(); nasal (	)) and LPS (fecal () nasal ()). Panel C: serologic responses to Invaplex
50  (IgA (©); IgG ()) and LPS (IgA (); IgG ()). Note: The horizontal lines denote the
minimum responder level. ASC = antibody secreting cell, PBMC = peripheral blood
mononuclear cell, and LPS = lipopolysaccharide.
group (pipette) was low (14%) as was  the magnitude of the ASC
response in the volunteer that responded to the vaccine.
3.5.2. Fecal and nasal IgA response
Fecal and nasal samples were collected pre-immunization and
on study days 21, 35, and 56 (Fig. 3B). Fecal IgA responder rates
were similar across all dose levels (∼60% responder rate, Table 5).
Among responders, there was a trend towards higher peak fold-
rises in antigen-specific fecal IgA in the 690 g dose group with
mean peak fold increases of 29 (range 5–71) and 25 (range 8–57)
for LPS and Invaplex 50-specific IgA, respectively, as compared to
12–17-fold increases over baseline in the 240 and 480 g dose
groups for each antigen. Nasal IgA responder rate had an apparent
dose–response for LPS (p = 0.03) and a similar trend for Invaplex
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50 (p = 0.13) (Table 5). LPS and Invaplex 50-specific mean peak fold
rises among responders in the 690 g dose group were 24 (range
7–77) and 7 (range 6–11), respectively (Table 6). Responder rates
in the 240 g (pipette) dose group were low for both Invaplex 50-
specific fecal (14–29%) and LPS-specific nasal IgA (14%).
3.5.3. Serological responses
LPS-specific plasma IgG response rates ranged from 40–46% and
Invaplex 50-specific response rates were 17–30% across all three
dose groups receiving the nasal spray (Table 5; Fig. 3C). Only a
small percentage (≤25%) of volunteers had LPS-specific plasma
IgA response regardless of vaccine dose. The Invaplex 50-specific
plasma IgA response rate ranged from 0 to 50% with the 690 g
dose group having the highest response rate (50%). No serocon-
version was detected after immunization with 240 g delivered
intranasally with a pipette.
3.5.4. Comparison between vaccine delivery methods
In general, higher ASC, plasma and mucosal immune responses
were noted in the group that received the 240 g via intranasal
spray compared to those volunteers receiving the same dose by
pipette (Table 5; Fig. 3A and B). Specifically, fecal IgA response rates
were two-fold higher against Invaplex 50 antigen (64% versus 29%;
p = 0.33) and four-fold higher against LPS (64% versus 14%; p = 0.07).
Plasma IgG responses to Invaplex 50 and LPS were not detected in
the pipette group, whereas the intranasal spray device group had
serological IgG responder rates of 27% and 46% to Invaplex 50 and
LPS antigens, respectively.
4. Discussion
The S. flexneri 2a Invaplex 50 intranasal vaccine was safe and
immunogenic in a double-blind, expanded safety and immuno-
genicity study. The results from the current trial are similar to
the results from the initial evaluation of the Invaplex 50 vaccine
[16] with respect to the absence of serious adverse events, low fre-
quency of adverse events and the vaccine being well tolerated. In
addition, there were several new aspects to the current trial as com-
pared to the previous clinical evaluation. In the current trial, a new
cGMP lot of Invaplex 50 manufactured using animal product-free
culture media was utilized. The differences in the culture medium
components did not impact the cGMP manufacture of the vaccine as
similar concentrations of the major vaccine constituents (LPS, IpaB
and IpaC) were achieved with Invaplex 50 lot 1307 as compared
with Invaplex 50 lot 0994, which was used in the previous trial.
Furthermore, both cGMP Invaplex 50 vaccine lots had comparable
levels of immunogenicity and protective efficacy in the mouse and
guinea pig models.
Another difference in the current trial is the use of a nasal spray
device rather than a pipette for delivery of the Invaplex 50 vac-
cine. To our knowledge, this is the first reported study in which the
DolphinTM intranasal spray device has been used in a human clinical
trial. Our evaluation of this device demonstrated favorable per-
formance characteristics in terms of device mechanical function,
product stability within the device, and reproducibility of spray
volumes in a clinical research setting. The observed higher immune
responses using the spray device compared to nasal pipette deliv-
ery suggests that the spray characteristics may  have facilitated
antigen presentation by enhancing uptake by M cells and delivery
to antigen presenting cells (APCs) of the mucosal immune sys-
tem [20]. Currently there is a licensed trivalent live-attenuated
influenza vaccine delivered by the intranasal route. The product
is safe and effective delivered as a large droplet aerosol (0.2 ml)
that deposits in the nasopharynx. Compared to parenteral admin-
istration of influenza split product vaccines, intranasal delivery of
live-attenuated virus has the potential advantage to induce both
systemic and broad mucosal immune responses [25]. Despite lower
hemagglutination inhibition titers in the intranasally delivered vac-
cine compared to the intramuscular delivered vaccine [26], they are
equally effective in preventing homologous influenza illness asso-
ciated infections [27,28]. Mucosally delivered influenza vaccine
also appears to provide evidence of immunity against heterologous
virus strains [26,29],  and is effective in priming immune responses
in young children [26,30].
Compared to the previous study in which the Invaplex 50
vaccine was  administered intranasally by pipette, the vaccine per-
formed similarly and was  well tolerated in humans when given
as an intranasal spray. In contrast to the previous study [16], we
noticed a trend towards an increase in local nasal signs and symp-
toms (sneezing, nasal itching, coughing) with increasing vaccine
dose among volunteers, a finding that was  reported in a prior
dose-escalation study of a proteosome-S. flexneri 2a LPS intranasal
vaccine [31]. However, similar to the prior Invaplex study, the
symptoms were mild, self-limited and well tolerated. Future stud-
ies utilizing a placebo group would be helpful in further evaluating
these findings.
There was  no significant difference in adverse events between
groups immunized with 240 g delivered via pipette or spray
device in the current study. However, there was  a trend towards
higher responder rates when the vaccine was delivered via the
DolphinTM spray device, mostly notably in the fecal IgA responder
rates. Modest increases in the responder rates for antigen-specific
plasma and ASC IgG were also achieved when the vaccine was
administered as a spray versus droplets with a pipette. Further-
more, increases in the immune responses were evident after
immunization with 690 g as compared to 480 or 240 g delivered
with the spray device suggesting a dose–response.
In addition to an increase in the responder rate post vaccina-
tion, the intranasal Invaplex 50 vaccine induced Shigella-specific
immune responses of comparable magnitude and frequency as
those immunized with live-attenuated Shigella vaccines [32]. Oral
immunization with 1 × 104 of the SC602 vaccine induced LPS-
specific IgA and IgG ASCs in 58% and 42% of volunteers, respectively,
and demonstrated protection against experimental challenge with
S. flexneri 2a 2457T (2 × 103 cfu) among individuals with peak
ASC values greater than 75 per 106 PBMC. In the current study,
intranasal immunization with Invaplex 50 (690 g) induced LPS-
specific ASCs in 58% of the volunteers. The magnitude of the ASC
responses induced after immunization with the oral SC602 vaccine
and Invaplex 50 vaccine were also similar with 33% of the volun-
teers having a ≥50 IgA ASC/106 PBMCs in each study. Although
the numbers of volunteers in each study were low, the data are
encouraging especially in light of the efficacy results in the SC602
study.
An equally important finding in the current study is the induc-
tion of strong mucosal IgA responses in the gastrointestinal tract
evidenced by antigen-specific fecal IgA and ASCs detected after
intranasal immunization with Invaplex 50. Presumably, when
PBMCs are collected from systemic circulation, ASCs are captured as
they were transiting from inductive sites to distal mucosal effector
sites. The homing potential of lymphocyte subsets is largely depen-
dent on the expression of key cell adhesion molecules. For mucosal
homing, it is widely accepted that 47 on lymphocytes is critical
for entry into the gut mucosa [33]. Although the present study has
not specifically addressed the expression of homing receptors on
lymphocytes collected after intranasal immunization, the antigen-
specific IgA ASCs and fecal IgA responses detected after intranasal
immunization with Invaplex 50 suggest that lymphocytes are hom-
ing to the gut, perhaps similar to what has recently been described
for a Norwalk virus-like particle (VLP) vaccine [34]. In that study,
intranasally administered Norwalk VLPs induced high levels of IgA
ASCs. The homing receptors on the IgA ASCs supported homing
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to the gut mucosa (47+/CD62L−) whereas VLP-specific IgG ASCs
expressed receptors indicative of homing to mesenteric and periph-
eral lymphoid tissues (47+/CD62L+). Furthermore, intranasal
immunization with Norwalk VLPs was unable to induce an immune
response in which the lymphocytes would home exclusively to
peripheral lymphoid tissues (47−/CD62L+). These findings may
help explain the low level of LPS and Invaplex 50-specific IgA and
IgG in the plasma after intranasal immunization with Invaplex 50.
Additional studies are required to determine if IgA ASCs induced
after Invaplex 50 immunization possess similar mucosal homing
adhesion molecules.
With respect to development of a Shigella vaccine, the ability
of a mucosally delivered subunit protein LPS complex vaccine to
induce both systemic and mucosal immune response would have
certain advantages in targeting colonization and invasion related
to Shigella pathogenesis. Nasal immunization with the Invaplex 50
product in clinical setting indicates that the Invaplex protein sub-
unit/LPS complex vaccine is well tolerated. In the current study,
the upper dose (690 g) contained 113 g of LPS in complex with
IpaB and IpaC proteins. It would appear that the dose of Invaplex
50 could be increased to attain a more potent immune response
given that S. flexneri 2a LPS has been given intranasally in pro-
teosomes at dose amounts of 1.34 mg  in a previous clinical trial
without serious adverse events [31]. However, a more concen-
trated Invaplex 50 vaccine would have to be manufactured as
the maximum dose (690 g) was given in the current trial due
to restrictions on the maximum volume (100 l) delivered by the
DolphinTM device. Finally, there are practical advantages to non-
needle delivery of vaccines (including intranasal delivery) in terms
of reducing the risks of needle stick injuries, as well as perhaps
being more acceptable to patients with aichmophobia. These per-
ceived benefits would need to be weighed with the potential extra
cost associated with device manufacture and packaging.
The results from this trial are encouraging and provide the nec-
essary data to advance the development of the Invaplex 50 vaccine.
The acceptable safety profile combined with the robust immune
response demonstrated at the 690 g dose warrants moving for-
ward into a phase 2b challenge study (proof of concept) to evaluate
vaccine efficacy, as well as expanded information on immuno-
genicity and safety in a placebo-controlled study. If efficacious,
development of a multivalent Shigella vaccine capable of provid-
ing immunological protection against S. flexneri 2a, S. sonnei,  and
S. dysenteriae 1 will be developed utilizing current manufactur-
ing processes would proceed towards field testing. Concurrently,
enhanced immunogenicity may  be achieved in the clinic with
second generation Invaplex 50 vaccines assembled from purified,
recombinant IpaB and IpaC and phenol-extracted LPS as has been
the case in pre-clinical evaluations in the mouse and guinea pig
models (Oaks and Kaminski, unpublished results). Further studies
evaluating vaccine dosing and regimens will also be required as
these products move through the vaccine development pipeline.
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